期刊
THERANOSTICS
卷 9, 期 1, 页码 90-103出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.30259
关键词
cancer; theranostic system; hypoxic tumor; ROS/GSH dual-activatable; cyclopeptide RA-V; fluorescence imaging
资金
- National Natural Science Foundation of China [21602255, 31470428]
- Natural Science Foundation of Jiangsu Province [BK20160745]
- National New Drug Innovation Major Project of Ministry of Science and Technology of China [2017ZX09309027]
- Program of Innovative Research Team of Jiangsu Province
- Fund of Chinese Academy of Sciences [XDA09030301-4]
- Fund for Introduction of High-level Talents from China Pharmaceutical University
- 111 Project from the Ministry of Education of China [B16046]
- State Administration of Foreign Experts Affairs of China
Activatable theranostic agents, which combine fluorescent reporters with masked chemotherapeutic agents that are activated by tumor-associated stimuli, would be attractive candidates to improve the tumor selectivity of chemotherapy. This work reports a ROS/GSH dual-activatable and O-2-evolving theranostic nanosystem (RA-S-S-Cy@PLGA NPs) for highly selective therapy against hypoxic tumors and in situ fluorescence-tracking of cancer chemotherapy. Methods: In this system, the newly designed theranostic agent (RA-S-S-Cy) is composed of a disulfide bond as a cleavable linker, a near infrared (NIR) active fluorophore as a fluorescent tracker, and a natural cyclopeptide RA-V as the active anti-cancer agent. Upon reaction with the high level of intracellular glutathione (GSH), disulfide cleavage occurs, resulting in concomitant active drug RA-V release and significant NIR fluorescence increase. To further improve the tumor targeting of RA-S-S-Cy and achieve redox dual-responsiveness, RA-S-S-Cy was incorporated into the c(RGDfK)-targeted PLGA nanoparticles together with an O-2-generating agent (catalase) to produce RA-S-S-Cy@PLGA NPs. Results: The cell-specific and redox dual-activatable release of RA-V lead to enhanced therapeutic outcomes in vivo and in vitro. More significantly, the RA-S-S-Cy@PLGA NPs were successfully applied for monitoring of drug release and chemotherapeutic efficacy in situ by turn-on NIR fluorescence. Conclusions: RA-S-S-Cy@PLGA NPs would be efficient theranostic nanosystems for more precise therapy against hypoxic tumors and provides a potential tool for deeper understanding of drug release mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据